RDIF

Kazakhstan becomes the first country outside Russia to authorize Sputnik M vaccine for adolescents

Retrieved on: 
Tuesday, February 22, 2022
Infection, Sputnik 1, Population, Lazzaro Spallanzani National Institute for Infectious Diseases, Ministry of Health (Russia), Ministry, Sputnik Light, Russian Direct Investment Fund, Equity, Republic, Ageing, Vaccine, Immunoglobulin G, VNA, Sputnik V COVID-19 vaccine, Vaccination, Communications satellite, Omicron, RDIF, Pfizer, COVID

Thus, Kazakhstan has become the first country outside Russia to authorize the use of Sputnik M.

Key Points: 
  • Thus, Kazakhstan has become the first country outside Russia to authorize the use of Sputnik M.
    In contrast with some international producers offering their vaccines in the same dosage for both adults and adolescents, the Gamaleya Center has developed Sputnik M specifically for adolescents.
  • Sputnik M is a two-shot vaccine based on the same human adenoviral vectors platform, which is safe and has been widely studied for over 30 years.
  • The only difference between Sputnik M and Sputnik V is a lower concentration of viral particles per dose: Sputnik M for adolescents has 5 times less concentration in comparison with the original Sputnik V in both shots.
  • Russian Ministry of Health registered Sputnik M on November 24, 2021 based on data from clinical trials confirming the high safety and immunogenicity profile of Sputnik M among adolescents.

Sputnik V vaccine granted full permanent approval in Russia

Retrieved on: 
Friday, February 4, 2022
Safety, List of health departments and ministries, Russian Direct Investment Fund, Coronavirus, Infection, COVID-19, Vaccination, Sputnik Light, Population, Pericarditis, V, Lazzaro Spallanzani National Institute for Infectious Diseases, Sputnik V COVID-19 vaccine, Vaccine, Immunoglobulin G, Equity, AstraZeneca, EUA, Myocarditis, Pharmaceutical industry, Omicron, Pfizer, RDIF

MOSCOW, Feb. 4, 2022 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces that the Russian Sputnik V vaccine against coronavirus has been granted full permanent approval by Russia's Health Ministry. It had previously held temporary emergency use authorization (EUA) from the Russian regulator.

Key Points: 
  • MOSCOW, Feb. 4, 2022 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces that the Russian Sputnik V vaccine against coronavirus has been granted full permanent approval by Russia's Health Ministry.
  • Sputnik V was authorized on August 11, 2020, becoming the world's first vaccine against COVID-19 to be granted emergency use authorization.
  • Sputnik V showed significantly smaller (2.6 times) reduction of virus neutralizing activity against Omicron as compared to reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold reduction for Pfizer vaccine).
  • Sputnik Light is based on recombinant human adenovirus serotype number 26 (the first component of Sputnik V).

Top Russian Colocation Provider IXcellerate Closes Latest Round of Funding to Accelerate Expansion Plans

Retrieved on: 
Tuesday, January 25, 2022
Internet, Security, Data Management, Technology, Software, Cloud, Leadership, Refinitiv, Ministry, Big data, Program, Russian Direct Investment Fund, ESG, Central Bank of Russia, Engineering, Life, Senior, Equity, Sberbank of Russia, Organization, Growth, Ministry of Finance (Azerbaijan), Orange Business Services, Banking in Russia, CIS, Solution, United Arab Emirates, Government, Agricultural Bank of China, Compliance, Huawei, Agricultural Bank, Security (finance), Renewable energy, Cryptocurrency, Financial services, RDIF, Mubadala Investment Company, IXcellerate, Mubadala Investment Company, Sberbank, Russian Direct Investment Fund, IXCELLERATE, MUBADALA INVESTMENT COMPANY, SBERBANK, RUSSIAN DIRECT INVESTMENT FUND

IXcellerate already offers world-class data center facilities and outstanding connectivity level in Russia to cater to both local enterprises and global corporations across multiple industries.

Key Points: 
  • IXcellerate already offers world-class data center facilities and outstanding connectivity level in Russia to cater to both local enterprises and global corporations across multiple industries.
  • As one of the largest carrier-neutral commercial data center operators in Russia, IXcellerate is enabling digitalization in Russia through unrivaled scalability and growth opportunities.
  • IXcellerate has a successful record in developing and managing state-of-the-art data centers in Russia.
  • The company is well-positioned to continue growing as a leading colocation and data center operator; directly enhancing Russia's digital infrastructure.

Venezuela received 7 mn doses of Sputnik Light booster in the biggest one-time global delivery of the one-shot Russian vaccine

Retrieved on: 
Tuesday, December 21, 2021
Hospital, Sputnik V COVID-19 vaccine, Vaccination, Pericarditis, Gamaleya Research Institute of Epidemiology and Microbiology, Infection, Sputnik 1, Technology, Equity, RNA transfection, AstraZeneca, City, Vaccine, Epitope, Myocarditis, Ministry, Coronavirus, Gamaleya, VNA, Sputnik Light, Russian Direct Investment Fund, RDIF, Delta, Omicron

MOSCOW, Dec. 21, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) today announced 7 million doses of Sputnik Light booster against coronavirus have been shipped to Venezuela becoming the biggest one-time global delivery of the one-shot vaccine.

Key Points: 
  • MOSCOW, Dec. 21, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) today announced 7 million doses of Sputnik Light booster against coronavirus have been shipped to Venezuela becoming the biggest one-time global delivery of the one-shot vaccine.
  • Sputnik Light is based on human adenovirus serotype 26 (the first component of Sputnik V).
  • Recent preliminary study announced by Gamaleya Institute showed that Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron.
  • Sputnik V standalone also induces robust neutralizing antibody response to Omicron variant, which is further strengthened by Sputnik Light booster.

Sistema PJSFC: Sistema increases effective stake in Binnopharm Group to 75.3%

Retrieved on: 
Monday, December 20, 2021
Stavropol, Russian Direct Investment Fund, Agriculture, OIBDA, LSE, Serpukhov, Company, PJSC, Tourism, Growth, Group, COVID-19, Financial Oversight and Management Board for Puerto Rico, SSA, VTB Bank, Marketing, VTB, Paper, London Stock Exchange, VTB Capital, London, Telecommunication, MOEX, RUB, Corporation, Partnership, SE, China Investment Corporation, The Group, Security (finance), Pharmaceutical industry, Sistema, Moscow Exchange, RDIF

As a result of the transaction, the Corporation's effective stake in Binnopharm Group has increased to 75.3%.

Key Points: 
  • As a result of the transaction, the Corporation's effective stake in Binnopharm Group has increased to 75.3%.
  • On 13 December 2021 the Group exercised its call option to acquire VTB's stake in Sinocom Investments Limited for RUB 9.06 billion.
  • On 28 July 2021, the Group exercised a call option to acquire VTB Bank (PJSC)'s stake in Ristango Holding Limited for RUB 6.7 billion.
  • As a result, Sistema has become the largest shareholder in Ristango Holding Limited and through it also Binnopharm Group, with an effective stake of 75.3%.

Recommendations of EMA and ongoing combo studies support mix&match approach pioneered by Sputnik team to fight COVID

Retrieved on: 
Tuesday, December 7, 2021
EMA, Research, Population, Mortality, Safety, Coronavirus, RNA transfection, Vaccine, Russian Direct Investment Fund, CEO, COVID, Vaccination, 2020 European Medicines Agency cyberattack, Sputnik Light, Antibody, RDIF, European Medicines Agency, Pfizer–BioNTech COVID-19 vaccine, AstraZeneca, Immunity, Infection, Ministry, Sputnik V COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry

Thus efficacy of Sputnik V on 6-8 months is much higher than officially published efficacy of mRNA vaccines.

Key Points: 
  • Thus efficacy of Sputnik V on 6-8 months is much higher than officially published efficacy of mRNA vaccines.
  • Sputnik Light as a booster helps other vaccines to increase their efficacy and has a high safety profile.
  • A study in Argentina on heterogeneous regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino has demonstrated Sputnik Light is an effective universal booster.
  • RDIF reiterates its offer to producers and countries to join efforts in protecting population through supplies of Sputnik V and Sputnik Light and their combination with other vaccines."

Face recognition and skeleton tracking developer 3DiVi nabs $2M

Retrieved on: 
Thursday, September 30, 2021
Time of flight, Capital, CCPA, GDPR, Artificial intelligence, Deep learning, Lidar, HAR, Solution, National Technological Initiative, API, Privacy, RDIF, Equity, Microsoft, Kinect, RVC, Russian Venture Company, Application-specific integrated circuit, SDK, IP, ML, Russian Direct Investment Fund, Visage SDK, Face, Growth, IOT, NTI, IDC, Algorithm, Intelligence, Intel, LG, Machine learning, Robotics, Time, Mobile phone, Cryptocurrency

Founded in 2011, 3DiVi is an AI technology company focused on the application of machine learning (ML) to computer vision.

Key Points: 
  • Founded in 2011, 3DiVi is an AI technology company focused on the application of machine learning (ML) to computer vision.
  • Successful commercial products born by this framework are Nuitrack Skeleton Tracking SDK (the popular alternative to Microsoft Kinect SDK, licensed by Intel, Orbbec, LG) and 3DiVi Face Recognition SDK.
  • Dmitry Morozov, co-founder of 3DiVi: "The company is already known in the computer vision market with SDKs for face and skeletal tracking.
  • Company main products are state-of-the-art API / SDKs for skeleton tracking, face recognition, object, and activity recognition.